Osseo IQ
Chapter 3 · Patient Selection & Medical Risk · §3.1

Patient Candidacy & Risk Stratification

Separating the few true contraindications from the many modifiable risks — and routing each to proceed, optimize, or decline.

Compiled by
Tan Khuu, DDS
Licensed dentist (CA & SC)
Audience
Oral surgeons, prosthodontists, periodontists & residents
Edition
1.0 · June 2026
Reviewed
June 2026 · next review June 2027
Reading time
~16 minutes
Evidence basis
Consensus statements + systematic reviews + primary literature
§3.1.1 — Overview

Few absolutes, many modifiers

Risk stratification is the discipline of deciding whether and how to place an implant before any drill touches bone. A clean medical history is rarely a yes-or-no question. The mistake of the inexperienced clinician is to read systemic disease as a list of prohibitions; the reality is that the great majority of medical conditions raise risk rather than forbid treatment. The clinician's task is therefore not to memorize a roster of contraindications but to sort each finding into the bucket that determines its disposition — and to recognize that most findings are modifiers the patient and clinician can work to neutralize.2

This chapter organizes that judgment around three buckets and three verdicts. Findings divide into absolute / defer risks — the rare true contraindications that stop the pathway; modifiable / optimize risks — the common conditions that elevate failure rate but respond to optimization; and local / site risks — anatomical or infective limitations addressed surgically. Each finding maps to one of three actions: proceed, optimize (then proceed), or decline / defer. The logic is sequential and conservative: a single absolute finding halts the pathway regardless of how favorable everything else looks, while modifiable risks route first to an optimization phase and only then to surgery.1

Most systemic conditions raise the risk of implant therapy; very few prohibit it. The work of candidacy is sorting which is which.
◆ Key concept · Three buckets, three verdicts

Absolute / defer findings (IV oncologic antiresorptives, recent head-and-neck radiotherapy to the site, unstable cardiac disease, active malignancy under treatment, skeletal immaturity) stop the pathway. Modifiable / optimize findings (smoking, diabetes, oral bisphosphonates, untreated periodontitis, poor hygiene) elevate risk but are correctable before surgery. Local / site findings (insufficient bone, nerve or sinus proximity, restricted space, active local infection) are managed surgically. The pathway runs the patient against the buckets in order of severity: the highest-tier finding present governs the verdict.

§3.1.2 — Screening

Sorting risk into three buckets

The first move at screening is classification, not decision. Before weighing how aggressively to optimize a smoker or how to graft a deficient ridge, the clinician must establish which category each finding belongs to, because category dictates the route. An absolute finding renders the modifiable and local analysis moot; a purely local finding does not invoke medical deferral. The table below collects the canonical findings of each bucket — the working vocabulary of candidacy.

Table 1 · The three risk buckets and how each routes
BucketRepresentative findingsDefault route
Absolute / defer High-dose IV / oncologic antiresorptives; recent head-and-neck radiotherapy to the site; recent MI or stroke / unstable cardiac disease; active malignancy under treatment; skeletal immaturity (growth incomplete) Decline / defer
Modifiable / optimize Smoking (RR ≈ 1.9 for failure); diabetes (target HbA1c ≤ 7–8%); oral bisphosphonates (MRONJ ≈ 0.5%); untreated periodontitis; poor oral hygiene / compliance Optimize, then proceed
Local / site Insufficient bone volume or quality; proximity to inferior alveolar nerve or maxillary sinus; limited inter-arch or mesiodistal space; active infection at site Manage surgically

Why the buckets are ordered, not parallel

The buckets are not weighed against one another like items on a balance; they are consulted in descending order of gravity. A patient on high-dose IV antiresorptives for metastatic disease is not made a candidate by a pristine ridge and impeccable hygiene. Conversely, a healthy non-smoker with a deficient ridge is not medically deferred — the constraint is local and surgical. This ordering is what lets a busy screening visit reach a defensible verdict quickly: identify the highest-tier finding present, and let it govern.2

§3.1.3 — Decision pathway

From dominant risk to verdict

The interactive selector below operationalizes the ordered logic. Run the patient against the three buckets in sequence and select the highest-tier finding present. A single absolute finding stops the pathway; a modifiable risk routes to an optimization phase before any commitment to surgery; absence of either yields a low-risk, standard-protocol verdict. The tool returns the corresponding pathway — proceed, optimize-then-proceed, or defer / decline — with the concrete next steps for each.

Interactive candidacy selector

Select the dominant risk finding to reveal its pathway, the rationale, and the ordered next steps.

Tap the highest-tier finding present in this patient.

✦ Clinical pearl · Optimize is a verdict, not a delay

The middle pathway is the one that distinguishes thoughtful candidacy from reflexive refusal. A modifiable finding does not mean "no" — it means "not yet, and here is the work." Cessation counseling for the smoker, glycemic control for the diabetic, periodontal stabilization for the perio patient: each is a defined optimization step that, once met, converts the patient into a candidate. Document the elevated risk in consent, intensify maintenance, and proceed once the target is reached.1

▲ Common pitfalls
  • Treating oral bisphosphonates as if they were IV oncologic antiresorptives — declining a patient whose MRONJ risk is roughly 0.5% rather than consenting and proceeding atraumatically.3
  • Reading "diabetes" as a single category. Well-controlled diabetes (HbA1c ≤ 7–8%) proceeds on routine protocol; poorly controlled diabetes is optimized first. The meta-analytic signal for diabetes as an independent failure risk is, in fact, weak when control is adequate.1
  • Placing into untreated active periodontitis, importing the patient's dysbiotic biofilm and inflammatory burden onto a fresh implant surface.
  • Quoting population risk figures as individual predictions during consent. The relative risk of smoking (≈ 1.9) is a population estimate, not a guarantee for the patient in the chair.
§3.1.4 — Quick reference

Common conditions at a glance

Most conditions modify rather than prohibit. The table below collapses the screening logic into a chairside reference: each condition resolves to a status and a concrete action, with the strength of the underlying evidence noted. Verify each finding against current medical guidance and coordinate with the patient's physician where indicated — risk figures are population estimates, not individual predictions.

Table 2 · Common conditions → status → action
ConditionStatusActionEvidence
SmokingModifiableCessation counseling; document elevated failure risk (RR ≈ 1.9)Meta-analysis
Diabetes (well-controlled)ProceedConfirm HbA1c ≤ 7–8%; routine protocolSyst. review
Diabetes (poorly controlled)Optimize firstDefer until glycemic control improvedConsensus
Oral bisphosphonatesCautionConsent for MRONJ (~0.5%); atraumatic techniquePosition paper
IV / oncologic antiresorptivesAvoidGenerally contraindicated; coordinate with oncologyPosition paper
Head & neck radiotherapyHigh riskSite/dose-dependent; specialist referral, weigh ORN riskMeta-analysis
Treated periodontitisOptimize firstStabilize before placement; strict maintenanceSyst. review
◆ Key concept · The two largest modifiable signals

Of the population-level risk factors quantified in the pooled literature, smoking (RR ≈ 1.9) and radiotherapy to the site (RR ≈ 2.3) carry the largest, most reproducible effects on implant failure; well-controlled diabetes, by contrast, shows no clear independent increase in pooled estimates. This is why cessation counseling and a careful radiotherapy history earn disproportionate attention at screening — they are the modifiable levers with the most evidence behind them.1

§3.1.5 — Glossary

Key terms

Absolute contraindication
A finding that prohibits routine implant therapy outright (e.g., high-dose IV oncologic antiresorptive therapy); stops the candidacy pathway.
Relative (modifiable) risk factor
A condition that elevates the probability of failure but can be reduced through optimization before surgery (e.g., smoking, hyperglycemia).
Local / site risk
An anatomical, volumetric, or infective limitation at the proposed site, addressed surgically rather than by medical deferral.
MRONJ
Medication-related osteonecrosis of the jaw — exposed or probeable necrotic bone in a patient on antiresorptive or antiangiogenic medication, persisting > 8 weeks, without a history of head-and-neck radiation.
ORN (osteoradionecrosis)
Non-healing irradiated bone exposed for > 3 months without tumor recurrence; the principal risk driving deferral after head-and-neck radiotherapy.
HbA1c
Glycated hemoglobin; an index of average glycemia over ~3 months, used to gauge whether a diabetic patient is sufficiently controlled (target ≤ 7–8%) to proceed.
Relative risk (RR)
The ratio of failure probability in exposed versus unexposed groups; a population estimate, not an individual prediction.
Optimization phase
The defined interval in which a modifiable risk is treated to target before implant surgery proceeds.
§3.1.S — Self-test

Board & fellowship preparation

1. The single most important principle of medical risk stratification before implant therapy is that:
B is correct. There are few true absolutes and many modifiers. The clinician's task is to sort findings into absolute, modifiable, and local buckets rather than treat all systemic disease as prohibitive.
2. Which of the following is best classified as an absolute / defer finding?
C is correct. High-dose IV / oncologic antiresorptives are generally contraindicated for elective implant placement. Diabetes, smoking, and treated periodontitis are modifiable risks.
3. The approximate relative risk of implant failure attributable to smoking in pooled meta-analytic data is closest to:
C is correct. The pooled meta-analytic estimate places smoking at RR ≈ 1.9 (about 1.92) for implant failure — a substantial but modifiable population-level effect.
4. A patient on oral bisphosphonates for osteoporosis requests an implant. The most appropriate action is:
B is correct. Oral bisphosphonates carry a low MRONJ risk (~0.5%). Document informed consent, use atraumatic surgery, and proceed — they are a caution, not an absolute contraindication.
5. The recommended glycemic target before elective implant placement in a diabetic patient is an HbA1c of approximately:
B is correct. A target HbA1c of ≤ 7–8% defines adequate control; below this, well-controlled diabetics proceed on routine protocol, while poorly controlled patients are optimized first.
6. A single absolute contraindication in an otherwise ideal candidate should:
B is correct. The buckets are consulted in descending order of gravity. A single absolute finding halts the pathway irrespective of how favorable the local and modifiable picture is.
7. Which finding is a local / site issue rather than a systemic one?
C is correct. Inadequate bone and nerve/sinus proximity are local-site constraints managed surgically (grafting, planning), not medical deferrals.
8. In pooled meta-analytic data, well-controlled diabetes as an independent risk factor for implant failure is best described as:
B is correct. Pooled estimates show no significant independent negative effect of diabetes (when reasonably controlled) on failure — in contrast to the clear signals for smoking and radiotherapy.
9. The verdict associated with a modifiable risk finding is:
B is correct. Modifiable findings route to an optimization phase — cessation, glycemic control, periodontal stabilization — and proceed once the target is met, with elevated risk documented in consent.
10. The principal long-term complication that drives deferral after head-and-neck radiotherapy to the implant site is:
B is correct. Irradiated bone is hypovascular and prone to osteoradionecrosis. Candidacy after radiotherapy is site- and dose-dependent and warrants specialist referral.
11. The approximate MRONJ risk for a patient on oral bisphosphonates undergoing implant placement is closest to:
B is correct. The MRONJ risk for oral bisphosphonate users is low — on the order of 0.5% — which justifies a caution-and-consent approach rather than refusal.
12. The correct screening sequence when classifying a patient's findings is:
B is correct. The buckets are ordered, not parallel. Identify the highest-tier finding present and let it govern the verdict.
13. For a high-dose IV / oncologic antiresorptive patient, the most appropriate coordination is with:
B is correct. IV/oncologic antiresorptive therapy is generally contraindicated for elective placement; any consideration must be coordinated with the patient's oncology team.
14. Which is the most appropriate management for a patient with untreated active periodontitis seeking an implant?
B is correct. Periodontitis is a modifiable risk: stabilize and re-evaluate first, then proceed with strict supportive maintenance.
15. Skeletal immaturity (incomplete growth) is classified as:
C is correct. Implants behave like ankylosed teeth and do not follow alveolar growth; placement in a growing patient risks infraocclusion, so therapy is deferred until skeletal maturity.
16. Which pair carries the largest, most reproducible population-level effect on implant failure?
B is correct. Pooled estimates show the clearest effects for smoking (RR ≈ 1.9) and radiotherapy (RR ≈ 2.3); diabetes shows no clear independent increase.
17. The output of the candidacy pathway is best summarized as one of:
B is correct. The three verdicts of the pathway are proceed (low risk), optimize-then-proceed (modifiable risk), and decline / defer (absolute or high risk).
18. When quoting a relative-risk figure such as smoking's RR ≈ 1.9 during informed consent, the clinician should remember that it is:
B is correct. Risk figures are derived from populations and describe average effects; they inform consent but do not predict the outcome for any single patient.
19. A recent myocardial infarction or unstable cardiac disease places the patient in which bucket?
C is correct. Unstable cardiac status is a deferral: postpone elective surgery until the patient is stabilized and cleared, coordinating with the treating physician.
20. When the candidacy pathway yields a decline / defer verdict, a reasonable additional step is to:
B is correct. A decline does not end care: offer non-implant prosthetic options (e.g., removable or fixed conventional prostheses) and record why implant therapy was deferred.
1. A medically complex patient is referred for implants. Describe the framework you use to decide candidacy, and explain why "few absolutes, many modifiers" is the right mental model.
Model answer. I sort every finding into one of three buckets — absolute / defer, modifiable / optimize, and local / site — and I consult them in descending order of gravity, letting the highest-tier finding govern. Most systemic conditions raise risk rather than prohibit treatment, so my default posture is to look for what I can optimize before reaching for refusal. A single absolute finding (IV oncologic antiresorptives, recent radiotherapy to the site, unstable cardiac disease, active malignancy under treatment, skeletal immaturity) stops the pathway. Modifiable findings (smoking, hyperglycemia, oral bisphosphonates, untreated periodontitis, poor hygiene) route to an optimization phase. Local findings are surgical problems, not medical deferrals. The output is always one of three verdicts: proceed, optimize-then-proceed, or decline / defer.
Examiner follow-ups:
  • Give me an example where a perfect ridge does not make the patient a candidate.
  • Why are the buckets ordered rather than scored against each other?
2. Contrast oral bisphosphonates with IV / oncologic antiresorptives in terms of candidacy, and justify the different dispositions.
Model answer. They sit in different buckets. Oral bisphosphonates, typically for osteoporosis, carry a low MRONJ risk on the order of 0.5%, so I treat them as a caution: I document informed consent specific to MRONJ, use atraumatic surgical technique, and proceed. High-dose IV or oncologic antiresorptives — given for skeletal metastases or hypercalcemia of malignancy — carry a substantially higher osteonecrosis risk and are generally contraindicated for elective placement; I coordinate with the oncology team and would not proceed routinely. The dose, route, indication, and cumulative exposure drive the difference, which is exactly why lumping all "bisphosphonate" patients together is a clinical error.
Examiner follow-ups:
  • What is MRONJ and how is it defined?
  • Does a drug holiday change your decision for the oral patient?
3. A patient with type 2 diabetes wants an implant. Walk me through how you decide whether to proceed.
Model answer. Diabetes is not a single category — control is what matters. I check the HbA1c: at a target of roughly 7–8% or better, the patient is well-controlled and I proceed on a routine protocol, because pooled data do not show a clear independent increase in failure for controlled diabetics. If the HbA1c is above target, I treat it as a modifiable risk — I defer elective surgery, coordinate with the patient's physician to improve glycemic control, and re-evaluate. Either way I document the disease in consent and intensify supportive maintenance, since the broader literature links hyperglycemia to impaired healing and infection.
Examiner follow-ups:
  • What does the meta-analytic evidence actually show for diabetes versus smoking?
  • How does poor glycemic control impair osseointegration mechanistically?
4. A patient had head-and-neck radiotherapy two years ago and now wants an implant in the irradiated field. How do you approach candidacy?
Model answer. Radiotherapy to the site is among the strongest population-level risk factors, with a relative risk for failure around 2.3, and the feared complication is osteoradionecrosis of hypovascular irradiated bone. So this is not a routine case. My decision is site- and dose-dependent: I establish the radiation dose to the planned site, the time since therapy, and the field geometry, and I refer for specialist input. I weigh the ORN risk explicitly, discuss it in consent, and consider adjuncts and alternatives. If the dose to the site is high or the field is unfavorable, I defer or decline and offer a non-implant prosthetic solution, documenting the rationale.
Examiner follow-ups:
  • What dose threshold raises your concern, and why?
  • How does ORN differ from MRONJ in pathophysiology?
5. Defend the claim that "optimize" is a verdict in its own right, not merely a delay, using a heavy smoker with otherwise good local conditions as your example.
Model answer. Optimize is an active disposition with defined work attached, not a holding pattern. Take the smoker: the pooled relative risk of failure is around 1.9, which is material but modifiable. Rather than reflexively refuse, I enroll the patient in cessation counseling, set a concrete goal, and document the elevated failure risk in consent — being clear that this is a population estimate, not an individual prediction. Once the modifiable lever has been addressed I proceed, and I intensify maintenance because the long-term risk persists. The alternative of declining a motivated smoker outright denies care for a risk the patient and I can actually work to reduce; the alternative of proceeding with no intervention ignores real, quantified harm. "Optimize" is the disciplined middle path between those two errors.
Examiner follow-ups:
  • What would make you escalate the smoker from optimize to defer?
  • How do you phrase the RR figure honestly during consent?
§3.1 — References

References

  1. Chen H, Liu N, Xu X, Qu X, Lu E. Smoking, radiotherapy, diabetes and osteoporosis as risk factors for dental implant failure: a meta-analysis. PLoS One. 2013;8(8):e71955. doi:10.1371/journal.pone.0071955. PMID: 23940794
  2. Diz P, Scully C, Sanz M. Dental implants in the medically compromised patient. J Dent. 2013;41(3):195–206. doi:10.1016/j.jdent.2012.12.008. PMID: 23313715
  3. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws — 2022 update. J Oral Maxillofac Surg. 2022;80(5):920–943. doi:10.1016/j.joms.2022.02.008. PMID: 35300956

Evidence grades: Systematic review / meta-analysis Consensus / position paper Preclinical. Risk figures are population estimates, not individual predictions.

About this chapter

This chapter is part of Osseo IQ — a clinical reference for implant dentistry. Content is sourced from consensus statements, systematic reviews, and primary literature; each key recommendation carries an evidence grade, and every page records its review date. Material is reviewed on a rolling annual cycle.

How to cite: Khuu T, ed. Patient Candidacy & Risk Stratification. In: Osseo IQ, 1st ed. §3.1. June 2026. Accessed [date]. [URL]

Compiled by: Tan Khuu, DDS — Doctor of Dental Surgery and a licensed dentist in California and South Carolina. Osseo IQ summarizes published evidence and clinical guidelines and is not a substitute for individual clinical judgment. Image credits: Schematic illustrations original © Osseo IQ, 2026.

For licensed clinicians — educational use only. This chapter summarizes published evidence and is not a substitute for individual clinical judgment, examination, medical consultation, or the standard of care in your jurisdiction. Coordinate complex medical cases with the patient's physician. Verify drug doses, devices, and protocols against current manufacturer instructions and local guidelines. Risk figures are population estimates, not individual predictions.

© 2026 Osseo IQ · Edition 1.0 · Chapter 3 Patient Selection & Medical Risk · §3.1 · Last reviewed June 2026